Pierre Giglio, MD

Pierre Giglio, MD

Physician

4.9 out of 5

Specialty:Neurooncology,Neurology

Gender: Male

Academic Title: Associate Professor in the College of Medicine

Research Program: Translational Therapeutics

  • About Me

    I am a neuro-oncologist specializing in more than 35 forms of nervous system cancers, with a research focus on glioblastoma. I also serve as an associate professor in the neurology department at the OSUCCC – James, and working alongside the talented cancer researchers and clinicians in the division of neuro-oncology is a truly rewarding experience. Additionally, I was named to the Castle Connolly list of “Regional Top Doctors” from 2015 to 2019. At The James, we are advocates for our patients and continuously seek new ways to provide the most effective treatments possible. Treating nervous system cancers requires a management approach that includes not just one physician but a team of specialists, including neurosurgeons, radiation oncologists, pathologists, neuroimaging specialists and more. Our team works with innovative technologies to perform genetic and molecular analysis of brain tumors. The combination of our expertise and technological capabilities at The James means patients receive individualized treatment plans for their specific needs. Research is also a major component of my career. As a member of the Translational Therapeutics Program at the OSUCCC – James, my research is focused on developing neuro-oncology clinical trials centering on newly diagnosed and recurrent glioblastoma, the most lethal form of brain cancer. I am particularly interested in designing clinical trials that feature targeted therapies for the treatments of patients with these tumors. I am also exploring cancer that has metastasized (spread) to the central nervous system in hopes of developing therapies based on correlative molecular studies. My work includes dozens of clinical research studies. Recently, I investigated a therapy for brain tumors utilizing components of the citrus, ginger and mushroom families that was published in the journal Tumor Biology. My work has also been published in several other top medical journals, including Anticancer Research and Neuro-Oncology. I have also presented my research to such organizations as the Brain Tumor Trials Collaborative, the International Symposium on Pediatric Neuro-Oncology and the American Society of Clinical Oncology.

  • Clinical Expertise

    • Skull Base Tumors
    • Metastasis Cancers
    • Brain Cancers
    • Glioblastoma
    • Pituitary Tumor
    • Hypercholesterolemia
    • Meningioma
    • Brain Stem Tumor
    • Hypertension
    • Gliomas
    • Spinal Cord Tumors
    • Neurosurgery
  • Where I See Patients

    Ohio State Brain and Spine Hospital

    Ohio State Brain and Spine Hospital

    Location Information
  • Education & Training

    Internship - Internal Medicine

    • University at Buffalo
      Ste 7230, Buffalo, NY

    Residency - Neurology

    • University at Buffalo
      Ste 7230, Buffalo, NY

    Fellowship - Psychiatry & Neurology, Neuromuscular Medicine

    • University of Chicago School of Medicine
      5841 S Maryland Ave, Chicago, IL

    Medical School

    • University of Malta Medical School
      Medical School, Block A, Level 0, Mater Dei Hospital, Guardamangia

    Fellowship - Neuro-oncology

    • University of Texas MD Anderson Cancer Center
      1515 Holcombe Blvd, Houston, TX
  • Academic Office & Contact Information

    Academic Office:

    410 W 10th Ave
    Columbus, Ohio 43210-1228

  • Reviews

    Patient Satisfaction Review

    The overall patient satisfaction rating is an average of all patient responses to the five questions gathered from the Outpatient Oncology survey, developed by Press Ganey Associates for use in oncology clinics across the country. On behalf of The James, Press Ganey administers the survey to patients who see our providers in an outpatient clinic office. For additional information about the patient satisfaction survey, please visit our Patient Satisfaction Survey page

    The comments are submitted by patients and reflect their view and opinions. The comments are not endorsed by and do not necessarily reflect the views of The James.

    4.9 out of 5 overall

    Kept you informed about your condition and treatment
    4.9 / 5
    Amount of time spent with you
    4.9 / 5
    Concern for your questions and issues
    4.9 / 5
    Skill and knowledge
    4.9 / 5
    Overall quality of care
    4.9 / 5

    Patient Comments

    Reviewed on December 16, 2024

    Dr. Gilio is incredible. It doesn't get any better. It is rare to find a doctor with his mix of intelligentce and personable nature. He will make sure his patients understand what is being told to them and genuinely cares abou their well-being.

    Reviewed on December 15, 2024

    Dr Gigilio takes the time to answer all questions and has all information needed to explain.

    Reviewed on December 12, 2024

    I had a follow-up visit with Dr. Giglio, and we discussed all of my questions.

    Reviewed on December 1, 2024

    Dr. Giglio is always upbeat, thorough, and encouraging.

    Reviewed on November 18, 2024

    I am very pleased with dr. G

    Reviewed on November 18, 2024

    I give you all a raving review because your ream deserves it

    Reviewed on September 8, 2024

    Excellent care and spent time answering all my questions

    Reviewed on September 3, 2024

    Best oncologist I've ever had in 15+ years

    Reviewed on September 2, 2024

    Very impressed with care and aware this doctor has helped coordinate with information to help plan for lymphoma chemo that needed to start quickly.

    Reviewed on June 10, 2024

    Dr. Giglio gives me excellent care. I know I'm in the best medical care when I'm seen by him.

    Reviewed on June 10, 2024

    A score of five isn't good enough for Dr. Giglio. He puts me so at ease and explains everything very clearly and calmly. I can't express how much I appreciate him.

    Reviewed on June 9, 2024

    I am fairly new to this provider and have a very complicated history and my condition has very available treatment. Dr Giglio listened so carefully, gave me time to ask all my questions, and carefully thought thru his recommendations.

    Reviewed on May 28, 2024

    We trust dr Giglio

    Reviewed on May 18, 2024

    Good

    Reviewed on April 17, 2024

    Great doctor.

    Reviewed on April 8, 2024

    They are doing a good job

    Reviewed on April 6, 2024

    They were very pleased with the amount of time the oncologist gave us in the examination and also in discussing options and what enters into those options.

    Reviewed on February 29, 2024

    This was my first appointment with this specific provider. I've never been more impressed by an experience with a doctor. In my opinion it went exactly how it should have gone in a perfect world, and ours is not a perfect world. I don't expect that level to be maintained, but the fact that the doctor was able to do it once, says much about the type of doctor they are and what level of care to expect at future visits.

    Reviewed on February 19, 2024

    I was high anxiety. He was patient, positive and ensured all questions were answered but he didn't push

    Reviewed on December 19, 2023

    Dr Giglio is a very caring doctor. He makes sure I understand everything and is incredibly thorough.

    Reviewed on August 31, 2023

    Doctor took the extra time needed to explain & deserve my many issues regarding my health.

    Reviewed on June 30, 2023

    Very good.

    Reviewed on June 24, 2023

    I love my doctor, he is very thourough and informative.

    Reviewed on June 10, 2023

    Dr. Giglio cares about his patients. He is a wonderful physician.

    Reviewed on June 6, 2023

    Dr. Giglio and the nurses that saw me were all very bright and helpful. Dr. Giglio was very thorough and showed me the relevant parts of the MRI scans. He is always very patient and kind. I am glad that if I need treatment some day I will be able to have it done at OSU.

    Reviewed on April 24, 2023

    Dr. Giglio and Dr. Li are excellent care providers. They take time to explain your situation and answer questions you may have.

    Reviewed on April 18, 2023

    Excellent care from all involved.

  • Publications

    April 1, 2024

    Final report of the phase II NEXT/CNS-GCT-4 trial: GemPOx followed by marrow-ablative chemotherapy for recurrent intracranial germ cell tumors.

    Shatara M, Blue M, Stanek J, Liu YA, Prevedello DM, Giglio P, Puduvalli VK, Gardner SL, Allen JC, Wong KK, Nelson MD, Gilles FH, Adams RH, Pauly J, O'Halloran K, Margol AS, Dhall G, Finlay JL

    Neurooncol Pract

    January 1, 2024

    Unsupervised machine learning models reveal predictive clinical markers of glioblastoma patient survival using white blood cell counts prior to initiating chemoradiation.

    Wang W, Kumm ZT, Ho C, Zanesco-Fontes I, Texiera G, Reis RM, Martinetto H, Khan J, McCandless MG, Baker KE, Anderson MD, Chohan MO, Beyer S, Elder JB, Giglio P, Otero JJ

    Neurooncol Adv

    December 4, 2023

    Glioblastoma pseudoprogression and true progression reveal spatially variable transcriptional differences.

    Wang W, Tugaoen JD, Fadda P, Toland AE, Ma Q, Elder JB, Giglio P, James Cancer Center Integrated Neuro-Oncology Team , Otero JJ

    Acta Neuropathol Commun

    February 1, 2023

    Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent IDH1- and IDH2-mutant Glioma.

    Fanucci K, Pilat MJ, Shyr D, Shyr Y, Boerner S, Li J, Durecki D, Drappatz J, Puduvalli V, Lieberman FS, Gonzalez J, Giglio P, Ivy SP, Bindra RS, Omuro A, LoRusso P

    Cancer Res Commun

    November 17, 2022

    Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial.

    Liau LM, Ashkan K, Brem S, Campian JL, Trusheim JE, Iwamoto FM, Tran DD, Ansstas G, Cobbs CS, Heth JA, Salacz ME, D'Andre S, Aiken RD, Moshel YA, Nam JY, Pillainayagam CP, Wagner SA, Walter KA, Chaudary R, Goldlust SA, Lee IY, Bota DA, Elinzano H, Grewal J, Lillehei K, Mikkelsen T, Walbert T, Abram S, Brenner AJ, Ewend MG, Khagi S, Lovick DS, Portnow J, Kim L, Loudon WG, Martinez NL, Thompson RC, Avigan DE, Fink KL, Geoffroy FJ, Giglio P, Gligich O, Krex D, Lindhorst SM, Lutzky J, Meisel HJ, Nadji-Ohl M, Sanchin L, Sloan A, Taylor LP, Wu JK, Dunbar EM, Etame AB, Kesari S, Mathieu D, Piccioni DE, Baskin DS, Lacroix M, May SA, New PZ, Pluard TJ, Toms SA, Tse V, Peak S, Villano JL, Battiste JD, Mulholland PJ, Pearlman ML, Petrecca K, Schulder M, Prins RM, Boynton AL, Bosch ML

    JAMA Oncol

    July 21, 2022

    Small Molecules and Immunotherapy Agents for Enhancing Radiotherapy in Glioblastoma.

    Matsui JK, Perlow HK, Ritter AR, Upadhyay R, Raval RR, Thomas EM, Beyer SJ, Pillainayagam C, Goranovich J, Ong S, Giglio P, Palmer JD

    Biomedicines

    June 11, 2022

    Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence.

    Kreatsoulas D, Bolyard C, Wu BX, Cam H, Giglio P, Li Z

    J Hematol Oncol

    March 31, 2022

    Phase I study of trametinib in combination with whole brain radiation therapy for brain metastases.

    Palmer JD, Prasad RN, Fabian D, Wei L, Yildiz VO, Tan Y, Grecula J, Welliver M, Williams T, Elder JB, Raval R, Blakaj D, Haglund K, Bazan J, Kendra K, Arnett A, Beyer S, Liebner D, Giglio P, Puduvalli V, Chakravarti A, Wuthrick E

    Radiother Oncol

    March 28, 2022

    Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study.

    Lassman AB, Sepúlveda-Sánchez JM, Cloughesy T, Gil-Gil MJ, Puduvalli VK, Raizer J, De Vos FYF, Wen PY, Butowski N, Clement PMJ, Groves MD, Belda-Iniesta C, Giglio P, Soifer HS, Rowsey S, Xu C, Avogadri F, Wei G, Moran S, Roth P

    Clin Cancer Res

    January 11, 2022

    Dose-escalated accelerated hypofractionation for elderly or frail patients with a newly diagnosed glioblastoma.

    Perlow HK, Yaney A, Yang M, Klamer B, Matsui J, Raval RR, Blakaj DM, Arnett A, Beyer S, Elder JB, Ammirati M, Lonser R, Hardesty D, Ong S, Giglio P, Pillainayagam C, Goranovich J, Grecula J, Chakravarti A, Gondi V, Brown PD, Palmer JD

    J Neurooncol

    November 1, 2021

    Hypofractionated Dose-Escalation for Elderly Patients With a Newly Diagnosed Glioblastoma Improves Survival.

    Perlow HK, Yang M, Klamer B, Raval R, Blakaj DM, Arnett ALH, Beyer S, Grecula JC, Ammirati M, Elder JB, Lonser RR, Hardesty D, Ong SS, Giglio P, Pillainayagam C, Goranovich J, Chakravarti A, Gondi V, Brown PD, Palmer JD

    Int J Radiat Oncol Biol Phys

    October 6, 2021

    Targeted Therapy for BRAF Mutant Brain Tumors.

    Rayi A, Alnahhas I, Ong S, Giglio P, Puduvalli VK

    Curr Treat Options Oncol

    October 1, 2021

    Assessment of Leptomeningeal Carcinomatosis Diagnosis, Management and Outcomes in Patients with Solid Tumors Over a Decade of Experience.

    Rinehardt H, Kassem M, Morgan E, Palettas M, Stephens JA, Suresh A, Ganju A, Lustberg M, Wesolowski R, Sardesai S, Stover D, Vandeusen J, Cherian M, Prieto Eibl MDPG, Miah A, Alnahhas I, Giglio P, Puduvalli VK, Ramaswamy B, Williams N, Noonan AM

    Adv Psychosom Med

    August 20, 2021

    Intraoperative 3 T MRI is more correlative to residual disease extent than early postoperative MRI.

    Huntoon K, Makary MS, Damante M, Giglio P, Slone W, Elder JB

    J Neurooncol

    April 15, 2021

    Impact of cerebrospinal fluid flow study in patients undergoing intrathecal chemotherapy via ventricular catheter reservoir.

    Eltobgy M, Huntoon K, Musgrave N, Shaikhouni A, Hardesty DA, Giglio P, Elder JB

    J Neurooncol

    February 1, 2021

    The role of VEGF receptor inhibitors in preventing cerebral radiation necrosis: a retrospective cohort study.

    Alnahhas I, Rayi A, Palmer JD, Raval R, Folefac E, Ong S, Giglio P, Puduvalli V

    Neurooncol Pract

    January 1, 2021

    Erratum to: Characterizing Benefit from Temozolomide in MGMT Promoter Unmethylated and Methylated Glioblastoma: A Systematic Review and Meta-analysis.

    Alnahhas I, Alsawas M, Rayi A, Palmer JD, Raval R, Ong S, Giglio P, Murad MH, Puduvalli V

    Neurooncol Adv

    January 1, 2021

    Prognostic implications of epidermal and platelet-derived growth factor receptor alterations in 2 cohorts of IDHwt glioblastoma.

    Alnahhas I, Rayi A, Guillermo Prieto Eibl MDP, Ong S, Giglio P, Puduvalli V

    Neurooncol Adv

    September 1, 2020

    False-positive 1p/19q Testing Results in Gliomas: Clinical and Research Consequences.

    Alnahhas I, Rayi A, Thomas D, Ong S, Giglio P, Puduvalli V

    Am J Clin Oncol

    March 13, 2020

    A Bayesian Adaptive Randomized Phase II Multicenter Trial of Bevacizumab with or without Vorinostat in Adults with Recurrent Glioblastoma.

    Puduvalli VK, Wu J, Yuan Y, Armstrong TS, Vera E, Wu J, Xu J, Giglio P, Colman H, Walbert T, Raizer J, Groves MD, Tran D, Iwamoto F, Avgeropoulos N, Paleologos N, Fink K, Peereboom D, Chamberlain M, Merrell R, Penas Prado M, Yung WKA, Gilbert MR

    Neuro Oncol

  • Consulting and Related Relationships

    At The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the university requires annual disclosures from all faculty members with external interests related to their university responsibilities. As of 09/30/2024, Dr. Giglio has reported relationships with the companies or entities listed below. If you have questions about the relationships listed below, please ask the faculty member. If you have questions about how these relationships are monitored by The Ohio State University Wexner Medical Center, please contact our Compliance Office.

    • Stocks